Bifogade filer
PDF
Kurs
+4,49%
Likviditet
0,19 MSEK
Kalender
| Tid* | ||
| 2025-05-14 | N/A | Årsstämma |
| 2025-05-14 | 08:30 | Kvartalsrapport 2025-Q1 |
| 2025-02-26 | 08:30 | Bokslutskommuniké 2024 |
| 2024-11-26 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-29 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-10 | - | X-dag ordinarie utdelning REDS 0.00 SEK |
| 2024-05-08 | - | Årsstämma |
| 2024-05-08 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-27 | - | Bokslutskommuniké 2023 |
| 2023-11-09 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-29 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-10 | - | X-dag ordinarie utdelning REDS 0.00 SEK |
| 2023-05-09 | - | Årsstämma |
| 2023-05-09 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-27 | - | Bokslutskommuniké 2022 |
| 2022-11-09 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-29 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-03 | - | X-dag ordinarie utdelning REDS 0.00 SEK |
| 2022-05-02 | - | Årsstämma |
| 2022-05-02 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-28 | - | Bokslutskommuniké 2021 |
| 2021-11-09 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-24 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | Årsstämma |
| 2021-05-05 | - | X-dag ordinarie utdelning REDS 0.00 SEK |
| 2021-05-03 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-19 | - | Extra Bolagsstämma 2021 |
| 2021-02-28 | - | Bokslutskommuniké 2020 |
| 2020-12-18 | - | Extra Bolagsstämma 2020 |
| 2020-11-09 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-24 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-23 | - | X-dag ordinarie utdelning REDS 0.00 SEK |
| 2020-06-22 | - | Årsstämma |
| 2020-05-04 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-25 | - | Bokslutskommuniké 2019 |
| 2019-11-18 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-26 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-07 | - | X-dag ordinarie utdelning REDS 0.00 SEK |
| 2019-05-06 | - | Årsstämma |
| 2019-05-06 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-26 | - | Bokslutskommuniké 2018 |
| 2018-08-27 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-08 | - | X-dag ordinarie utdelning REDS 0.00 SEK |
| 2018-05-07 | - | Årsstämma |
| 2018-02-27 | - | Bokslutskommuniké 2017 |
| 2017-09-25 | - | Extra Bolagsstämma 2017 |
| 2017-08-28 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-06 | - | X-dag ordinarie utdelning REDS 0.00 SEK |
| 2017-04-05 | - | Årsstämma |
| 2017-02-22 | - | Bokslutskommuniké 2016 |
| 2016-10-26 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-09 | - | Årsstämma |
| 2016-05-09 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-23 | - | X-dag ordinarie utdelning REDS 0.00 SEK |
| 2016-02-22 | - | Bokslutskommuniké 2015 |
| 2015-11-27 | - | Kvartalsrapport 2015-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
On May 5, 2023, Reps. Adrian Smith (R-NE) and Melanie Stansbury (D-NM) introduced the Home Dialysis Risk Prevention Act. The legislation ensures that patients undergoing home dialysis have access to blood loss detection devices that will alert them if blood loss from venous needle dislodgement (VND) is detected.
"We are pleased that US House of Representatives is addressing patient safety for hemodialysis at home with this this important bill. Redsense's focus is on providing increased patient safety for home hemodialysis. We look forward to the advancement of this bill." says Pontus Nobréus CEO of Redsense Medical.
Further information about the bill can be found through the link: https://adriansmith.house.gov/media/press-releases/smith-stansbury-introduce-bipartisan-bill-improve-home-dialysis-patient-safety
About venous needle dislodgement (VND)
During hemodialysis, the patient's bloodstream is connected to an artificial kidney machine outside of the body using vascular access. The purified blood is returned to the patient through venous needle access. If the venous needle dislodges, the patient loses a lot of blood quickly if it is not immediately detected. Unpredictable VND can happen to any dialysis patient, at any time. VND has been estimated to occur more than 300 times a day in the United States alone and poses a serious safety risk for the patient.
For more information, please contact:
Pontus Nobréus, CEO
Telephone: +46 72-171 1264
E-mail: pontus.nobreus (at) redsensemedical.com
Redsense Medical AB (publ), 556646-4862